Solution for endometrial cancer, eliminating cancer at the stage of precancerous lesions. Endometrial cancer is one of the three major malignant cancers in gynecology.
Endometrial cancer is one of the most common malignant cancers in the female reproductive system, ranking second among female reproductive system malignancies in China, and is more prevalent in urban women. According to statistics from the International Agency for Research on Cancer of the World Health Organization, there were approximately 420,000 new cases of endometrial cancer worldwide in 2020, with about 100,000 deaths.
Of these cases, approximately 82,000 new cases of endometrial cancer were reported in China, with about 16,000 deaths. It is estimated that by 2035, there will be 93,000 new cases of endometrial cancer in China.
The cure rate for early-stage endometrial cancer is extremely high, with a 5-year survival rate of up to 95%. However, the 5-year survival rate for stage IV endometrial cancer is only 19%.
Endometrial cancer is more common in postmenopausal and perimenopausal women, with an average onset age of around 55 years. However, in recent years, there has been an increasing trend in the incidence of endometrial cancer among women aged 40 and below.
There is currently no appropriate screening method for endometrial cancer
For women of childbearing age, early screening and timely management of endometrial cancer can maximize the preservation of fertility and provide a chance for long-term survival.
However, currently there are no sensitive and accurate non-invasive screening methods for endometrial cancer in clinical practice. Symptoms such as irregular vaginal bleeding and vaginal discharge in the early stages are easily overlooked, resulting in a missed opportunity for early diagnosis.
Preliminary screening using ultrasound imaging and routine gynecological examinations has low sensitivity.
The use of hysteroscopy and pathological biopsy is invasive, with high anesthesia and cost, and may result in bleeding, infection, and uterine perforation, leading to a high rate of missed diagnosis, and is not used as a routine screening method.
Endometrial biopsy sampling may cause discomfort, bleeding, infection, and uterine perforation, leading to a high rate of missed diagnosis.
TAGMe DNA Methylation Detection Kits (qPCR) for Endometrial Cancer Launches the Era of Endometrial Cancer Diagnosis and Treatment 2.0
TAGMe DNA Methylation Detection Kits (qPCR) for Endometrial Cancer can effectively complement the shortcomings of conventional screening methods for endometrial cancer, greatly reducing the missed diagnosis rate and helping patients to detect cancer signals in a timely manner.
Double-blind testing is the "gold standard" for technical validation and also the clinical standard that Epiprobe has always adhered to!
The results of the double-blind testing showed that for cervical scrape samples, the AUC was 0.86, specificity was 82.81%, and sensitivity was 80.65%; for uterine cavity brush samples, the AUC was 0.83, specificity was 95.31%, and sensitivity was 61.29%.
For cancer early screening products, the core objective is to screen out potentially problematic individuals rather than making a definitive diagnosis.
For cancer early screening products, considering that the purpose of user's usage is to eliminate the risk of illness and to avoid missed diagnoses as much as possible is the greatest sincerity towards the tested individuals.
The negative predictive value of TAGMe DNA Methylation Detection Kits (qPCR) for Endometrial Cancer is 99.4%, which means that in the population of people who receive negative results, 99.4% of the negative results are true negatives. The ability to prevent missed diagnoses is very outstanding, and the vast majority of negative users can rest assured that they do not need to undergo invasive screening with high missed diagnosis rates. This is the greatest protection for users.
Self-assessment of risk factors for endometrial cancer.
With the improvement of living standards, the incidence of endometrial cancer in China has been increasing year by year, and there is a trend towards younger patients.
So, what kind of people are more likely to develop endometrial cancer?
Generally speaking, people who are more likely to develop endometrial cancer have the following six characteristics:
- Suffer from metabolic syndrome: a disease characterized by obesity, especially abdominal obesity, as well as high blood sugar, abnormal blood lipids, high blood pressure, etc., which seriously affects the health of the body;
- Long-term single estrogen stimulation: long-term exposure to single estrogen stimulation without corresponding progesterone to protect the endometrium;
- Early menarche and late menopause: this means that the number of menstrual cycles increases, so the endometrium is exposed to estrogen stimulation for a longer period of time;
- Not giving birth to children: during pregnancy, the level of progesterone in the body is high, which can protect the endometrium;
- Genetic factors: the most classic one is Lynch syndrome. If there are young cases of colorectal cancer, stomach cancer, or female relatives with ovarian cancer, endometrial cancer, etc. among close relatives, it should be noted and genetic counseling and evaluation can be done;
- Unhealthy lifestyle habits: such as smoking, lack of exercise, and a preference for high-calorie and high-fat foods such as potato chips, french fries, milk tea, fried foods, chocolate cakes, etc., so it is necessary to exercise more after consuming them.
You can compare yourself with the 6 characteristics above that are more likely to develop endometrial cancer, and try to correct them as much as possible to prevent it from the source.
Post time: May-09-2023